Advicenne Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Didier Laurens

İcra Kurulu Başkanı

€268.0k

Toplam tazminat

CEO maaş yüzdesi	75.9%
CEO görev süresi	3.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	6.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Didier Laurens'un ücretlendirmesi Advicenne'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€8m
Dec 31 2023	€268k	€203k	-€7m
Sep 30 2023	n/a	n/a	-€9m
Jun 30 2023	n/a	n/a	-€10m
Mar 31 2023	n/a	n/a	-€11m
Dec 31 2022	€242k	€190k	-€11m
Sep 30 2022	n/a	n/a	-€10m
Jun 30 2022	n/a	n/a	-€9m
Mar 31 2022	n/a	n/a	-€11m
Dec 31 2021	€130k	€86k	-€12m

Tazminat ve Piyasa: Didier 'nin toplam tazminatı ($USD 282.84K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 476.59K ).

Tazminat ve Kazançlar: Didier şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Didier Laurens (57 yo)

3.5yrs

Görev süresi

€267,987

Tazminat

Mr. Didier Laurens serves as Chief Executive Officer at Advicenne S.A. since May 3, 2021 and serves as its Director, MD and General Director. He is Chief Financial Officer of surgical robotics company eCen...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Didier Laurens	CEO, MD	3.5yrs	€267.99k	Veri yok
Laurent Cassedanne	Deputy CEO	3.2yrs	€175.30k	Veri yok
Isabelle Kervella	Chief Financial Officer	no data	Veri yok	Veri yok
André Ulmann	Chief Medical Officer & Non-Voting Director	3.8yrs	Veri yok	Veri yok
Hege Hellstrom	Chief Commercial Officer	no data	Veri yok	Veri yok
Robbie McCarthy	General Manager of Advicenne Inc.	no data	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 3MM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Didier Laurens	CEO, MD	2.4yrs	€267.99k	Veri yok
Laurent Cassedanne	Deputy CEO	no data	€175.30k	Veri yok
André Ulmann	Chief Medical Officer & Non-Voting Director	2.4yrs	Veri yok	Veri yok
Philippe Boucheron	Chairman of the Board	13.6yrs	Veri yok	Veri yok
Thibaut Roulon	Director	13.6yrs	Veri yok	Veri yok
Catherine Dunand	Director	7.7yrs	Veri yok	Veri yok
Charlotte Sibley	Independent Director	6.2yrs	€5.00k	Veri yok
Larry Greenbaum	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bertrand Knebelmann	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gema Ariceta	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Elena Levtchenko	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Detlef Bockenhauer	Member of Scientific Advisory Board	5yrs	Veri yok	Veri yok

6.2yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 3MM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).

Advicenne Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Advicenne S.A. Announces Executive Changes

Advicenne Appoints Philippe Boucheron as Chairman of Its Board of Directors

Advicenne Appoints Peter Meeus as Chief Executive Officer, Effective February 15, 2021

Recent updates

Advicenne S.A. to Report First Half, 2025 Results on Sep 18, 2025

Less than half of directors are independent

Advicenne Achieves Major Milestones in the US Due to Several Positive FDA Opinion on ADV7103

Full year 2023 earnings released: €0.67 loss per share (vs €1.16 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Advicenne S.A. to Report First Half, 2024 Results on Sep 18, 2024

Advicenne S.A. to Report Fiscal Year 2022 Results on Mar 30, 2023

Advicenne Updates on Availability of Sibnayal to Patients and Caregivers in Great Britain

Advicenne Announces Commercial Launch of Sibnayal in Great Britain

Advicenne S.A. Announces Executive Changes

Advicenne Appoints Philippe Boucheron as Chairman of Its Board of Directors

Advicenne Announces the Release of Results of a Study Showing Improved Quality of Life in Patients Living With DRTa and Treated by ADV7103

Advicenne Ordinary Shareholders' Meeting Approves Delisting from Regulated Market of Euronext Brussels

Forecast to breakeven in 2023

Advicenne Announces Positive Opinion from the French Transparency Commission (HAS) for Its Drug Sibnayal™ in dRTA

First half 2021 earnings released: €0.93 loss per share (vs €0.92 loss in 1H 2020)

Advicenne Receives Medicines and Healthcare products Regulatory Agency Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

Advicenne S.A. announced that it has received €9.42128 million in funding

Chief Executive Officer Peter Meeus has left the company

Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

Advicenne Expects Imminent Marketing Authorization for ADV7103 (Sibnayal™) for dRTA in Europe

Advicenne S.A. Provides an Update as its Operations Evolve

New 90-day high: €12.10

New 90-day high: €11.70

Advicenne Appoints Peter Meeus as Chief Executive Officer, Effective February 15, 2021

Advicenne Receives Positive CHMP Opinion Recommending Approval of ADV7103 (sibnayal) for the Treatment of Distal Renal Tubular Acidosis (dRTA)

New 90-day high: €8.46

New 90-day high: €7.58

New 90-day low: €5.96

New 90-day low: €6.46

First half earnings released

New 90-day low - €6.64

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş